content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001781605</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001830214</issuerCik>
        <issuerName>Ginkgo Bioworks Holdings, Inc.</issuerName>
        <secFileNumber>001-40097</secFileNumber>
        <issuerAddress>
          <com:street1>27 DRYDOCK AVENUE</com:street1>
          <com:street2>8TH FLOOR</com:street2>
          <com:city>BOSTON</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02210</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>(877) 442-5362</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Novalis LifeSciences Investments I, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Director</relationshipToIssuer>
          <relationshipToIssuer>Footnote #1 (See Remarks)</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Class A Common Stock</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>Cowen and Company, LLC</name>
          <address>
            <com:street1>599 Lexington Ave Floor 21</com:street1>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10022</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>265000</noOfUnitsSold>
        <aggregateMarketValue>220029.50</aggregateMarketValue>
        <noOfUnitsOutstanding>1709063953</noOfUnitsOutstanding>
        <approxSaleDate>05/16/2024</approxSaleDate>
        <securitiesExchangeName>NYSE</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Class A Common Stock</securitiesClassTitle>
        <acquiredDate>09/17/2021</acquiredDate>
        <natureOfAcquisitionTransaction>SPAC/Business Combination</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Novalis LifeSciences Investments I, L.P.</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>265000</amountOfSecuritiesAcquired>
        <paymentDate>09/17/2021</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <securitiesSoldInPast3Months>
        <sellerDetails>
          <name>Marijn E. Dekkers</name>
          <address>
            <com:street1>27 Drydock Avenue, 8th floor</com:street1>
            <com:city>Boston</com:city>
            <com:stateOrCountry>MA</com:stateOrCountry>
            <com:zipCode>02210</com:zipCode>
          </address>
        </sellerDetails>
        <securitiesClassTitle>Ginkgo Bioworks Holdings, Inc - Class A</securitiesClassTitle>
        <saleDate>05/14/2024</saleDate>
        <amountOfSecuritiesSold>1727056</amountOfSecuritiesSold>
        <grossProceeds>1605120.56</grossProceeds>
      </securitiesSoldInPast3Months>
      <remarks>(1) Novalis LifeSciences Investments I GP, LLC is the general partner (the General Partner) of Novalis LifeSciences Investment I, L.P. (the Fund). Marijn E. Dekkers is the Manager of the General Partner and has sole voting and Investment control over all of the shares of the Issuer held by the Fund. Marijn E. Dekkers is a member of the Board of Directors of the Issuer. The Fund is a less than ten percent stockholder of the issuer.</remarks>
      <noticeSignature>
        <noticeDate>05/16/2024</noticeDate>
        <signature>Marijn E. Dekkers</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4026}]
text: 144
  0001781605
  XXXXXXXX
  LIVE
  0001830214
  Ginkgo Bioworks Holdings, Inc.
  001-40097
  27 DRYDOCK AVENUE
  8TH FLOOR
  BOSTON
  MA
  02210
  (877) 442-5362
  Novalis LifeSciences Investments I, L.P.
  Director
  Footnote #1 (See Remarks)
  Class A Common Stock
  Cowen and Company, LLC
  599 Lexington Ave Floor 21
  New York
  NY
  10022
  265000
  220029.50
  1709063953
  05/16/2024
  NYSE
  Class A Common Stock
  09/17/2021
  SPAC/Business Combination
  Novalis LifeSciences Investments I, L.P.
  N
  265000
  09/17/2021
  Cash
  N
  Marijn E. Dekkers
  27 Drydock Avenue, 8th floor
  Boston
  MA
  02210
  Ginkgo Bioworks Holdings, Inc - Class A
  05/14/2024
  1727056
  1605120.56
  (1) Novalis LifeSciences Investments I GP, LLC is the general partner (the General Partner) of Novalis LifeSciences Investment I, L.P. (the Fund). Marijn E. Dekkers is the Manager of the General Partner and has sole voting and Investment control over all of the shares of the Issuer held by the Fund. Marijn E. Dekkers is a member of the Board of Directors of the Issuer. The Fund is a less than ten percent stockholder of the issuer.
  05/16/2024
  Marijn E. Dekkers